A Study of PY314 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects
with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or
relapsed to standard of care (including pembrolizumab, if approved for that indicati...
Age: 18 years - 66+
Gender: All
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of
BT8009 given as a single agent and in combination with pembrolizumab in participants with
advanced solid tumors associated with Nectin-4 expression or in participants with a...
Age: 18 years - 66+
Gender: All
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Triple negative breast cancer (TNBC) represents about 15% of breast cancers and is
characterized by the lack of expression of estrogen receptor (ER), progesterone receptor
(PR), and HER-2 non-amplification. Women with TNBC tend to be younger, African American, and
...
Age: 18 years - 66+
Gender: Female